Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) entered into a settlement agreement with Teva Pharmaceuticals Industries Ltd ...

Teva Pharmaceutical Industries Ltd (TEVA) stock saw a decline, ending the day at $21.49 which represents a decrease of $-0.11 or -0.51% from the prior close of $21.6. The stock opened at $21.59 and ...

BofA keeps a Buy rating on Catalyst Pharmaceuticals (CPRX) with a $30 price target following the announcement of a Firdapse patent settlement ...

In its survey of the Internet sector, Cantor Fitzgerald selected Wix, led by CEO Avishai Abrahami, as a top pick, along with ...

Catalyst (CPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med ...

Shares of Catalyst Pharmaceuticals rose as the company reached a settlement agreement with Teva Pharmaceuticals related to Teva's plans for a generic version of Firdapse 10 mg tablets. Catalyst stock ...

Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing ...

Citi analyst Samantha Semenkow has maintained their bullish stance on CPRX stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...

Catalyst Pharmaceuticals (NASDAQ:CPRX) stock jumped 15% Wednesday on news the company had reached an agreement with Teva ...

The news caused a significant decline in the price of Zeta stock. On November 13, 2024, the price of the company's stock fell 37%, from a closing price of $28.22 per share on November 12, 2024, to $17 ...